[go: up one dir, main page]

WO2001079496A3 - Ligand for herpes simplex virus entry mediator and methods of use - Google Patents

Ligand for herpes simplex virus entry mediator and methods of use Download PDF

Info

Publication number
WO2001079496A3
WO2001079496A3 PCT/US2001/011857 US0111857W WO0179496A3 WO 2001079496 A3 WO2001079496 A3 WO 2001079496A3 US 0111857 W US0111857 W US 0111857W WO 0179496 A3 WO0179496 A3 WO 0179496A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
ligand
entry mediator
virus entry
herpes simplex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/011857
Other languages
French (fr)
Other versions
WO2001079496A2 (en
Inventor
Carl F Ware
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Institute for Allergy and Immunology
Original Assignee
La Jolla Institute for Allergy and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/524,325 external-priority patent/US6998108B1/en
Application filed by La Jolla Institute for Allergy and Immunology filed Critical La Jolla Institute for Allergy and Immunology
Priority to JP2001577479A priority Critical patent/JP2003531152A/en
Priority to CA2406132A priority patent/CA2406132C/en
Priority to DE60129010T priority patent/DE60129010T2/en
Priority to AU5338701A priority patent/AU5338701A/en
Priority to EP01926879A priority patent/EP1274840B1/en
Publication of WO2001079496A2 publication Critical patent/WO2001079496A2/en
Publication of WO2001079496A3 publication Critical patent/WO2001079496A3/en
Anticipated expiration legal-status Critical
Priority to AU2007201279A priority patent/AU2007201279B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A novel polypeptide ligand, p30, or LIGHT, for herpes virus entry mediator, HVEM, is provided. p30 is useful for modulating immune responses and in inhibiting infection and/or subsequent proliferation by herpes virus. HVEM fusion proteins are also provided. Methods for treating subjects with lymphoid cell disorders, tumors, autoimmune diseases, inflammatory disorders of those having or suspected of having a herpes virus infection, utilizing p30 and the fusion proteins of the invention, are also provided.
PCT/US2001/011857 2000-03-13 2001-04-11 Ligand for herpes simplex virus entry mediator and methods of use Ceased WO2001079496A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2001577479A JP2003531152A (en) 2000-04-12 2001-04-11 Ligands to herpes simplex virus entry mediators and methods of use
CA2406132A CA2406132C (en) 2000-04-12 2001-04-11 Ligand for herpes simplex virus entry mediator and methods of use
DE60129010T DE60129010T2 (en) 2000-04-12 2001-04-11 LIGAND OF THE CELL INTRUSION-PROCESSING PROTEIN OF HERPES SIMPLEX AND METHODS FOR ITS USE
AU5338701A AU5338701A (en) 2000-04-12 2001-04-11 Ligand for herpes simplex virus entry mediator and methods of use
EP01926879A EP1274840B1 (en) 2000-04-12 2001-04-11 Ligand for herpes simplex virus entry mediator and methods of use
AU2007201279A AU2007201279B2 (en) 2000-03-13 2007-03-23 Ligand for herpes simplex virus entry mediator and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/524,325 US6998108B1 (en) 1997-07-07 2000-03-13 Antibodies to p30 polypeptides and methods making and using same
US54909600A 2000-04-12 2000-04-12
US09/549,096 2000-04-12

Publications (2)

Publication Number Publication Date
WO2001079496A2 WO2001079496A2 (en) 2001-10-25
WO2001079496A3 true WO2001079496A3 (en) 2002-08-29

Family

ID=27061465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011857 Ceased WO2001079496A2 (en) 2000-03-13 2001-04-11 Ligand for herpes simplex virus entry mediator and methods of use

Country Status (1)

Country Link
WO (1) WO2001079496A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771013B2 (en) * 1996-03-22 2004-03-11 Human Genome Sciences, Inc. Apoptosis inducing molecule II
EP1179347A4 (en) * 1999-05-21 2002-06-26 Takeda Chemical Industries Ltd HEPATIC FUNCTION REGULATORS
EP1336619A3 (en) * 2002-02-19 2003-12-10 Millenium Pharmaceuticals, Inc. Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
CA2482938A1 (en) * 2002-04-12 2003-10-23 Human Genome Sciences, Inc. Antibodies that specifically bind to tr2
FR2845692A1 (en) * 2002-10-15 2004-04-16 France Hybrides Producing mammals resistant to infection by alpha-herpes virus, particularly pigs resistant to pseudorabies, by expressing transgene encoding fusion of receptor domain and immunoglobulin
US7811983B2 (en) 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
CA2529058A1 (en) * 2003-06-11 2005-01-13 The University Of Chicago Increased t-cell tumor infiltration by mutant light
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
EP2207597B1 (en) 2007-09-18 2020-02-19 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
EP2790730B1 (en) 2011-12-15 2019-01-23 The University of Chicago Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
CN118562020B (en) * 2024-06-20 2025-07-29 首都医科大学 Glu-His-Gly trimer, preparation and application thereof in enhancing immunity

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004658A1 (en) * 1995-07-28 1997-02-13 Northwestern University Herpes simplex virus 1 entry into cells mediated by a novel member of the tnf/ngf receptor family
WO1997034911A1 (en) * 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
WO1998003648A1 (en) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Fas ligand-like protein, its production and use
WO1998017313A2 (en) * 1996-10-25 1998-04-30 Biogen, Inc. Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
WO1998018824A1 (en) * 1996-10-30 1998-05-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
WO1998025967A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof
WO1998051346A1 (en) * 1997-05-12 1998-11-19 Smithkline Beecham Corporation Human tumor necrosis factor receptor-like 2 (tr2) antibodies
WO1999002563A1 (en) * 1997-07-07 1999-01-21 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
EP0897114A2 (en) * 1997-08-13 1999-02-17 Smithkline Beecham Corporation A method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
WO1999011662A1 (en) * 1997-09-05 1999-03-11 Millennium Biotherapeutics, Inc. Novel molecules of the tnfr-ligand-related protein family and uses thereof
WO1999035262A2 (en) * 1998-01-07 1999-07-15 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
WO1999042584A1 (en) * 1998-02-20 1999-08-26 Human Genome Sciences, Inc. Apoptosis inducing molecule ii and methods of use
WO2000010591A1 (en) * 1998-08-18 2000-03-02 The Trustees Of The University Of Pennsylvania Peptides for inhibition of herpes simplex virus entry
WO2000014230A1 (en) * 1998-09-03 2000-03-16 Millennium Pharmaceuticals, Inc. Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof
WO2000021558A1 (en) * 1998-10-09 2000-04-20 Biogen, Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
WO2000053223A1 (en) * 1999-03-11 2000-09-14 Human Genome Sciences, Inc. Apoptosis inducing molecule ii and methods of use

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004658A1 (en) * 1995-07-28 1997-02-13 Northwestern University Herpes simplex virus 1 entry into cells mediated by a novel member of the tnf/ngf receptor family
WO1997034911A1 (en) * 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
WO1998003648A1 (en) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Fas ligand-like protein, its production and use
WO1998017313A2 (en) * 1996-10-25 1998-04-30 Biogen, Inc. Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
WO1998018824A1 (en) * 1996-10-30 1998-05-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
WO1998025967A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof
WO1998051346A1 (en) * 1997-05-12 1998-11-19 Smithkline Beecham Corporation Human tumor necrosis factor receptor-like 2 (tr2) antibodies
WO1999002563A1 (en) * 1997-07-07 1999-01-21 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
EP0897114A2 (en) * 1997-08-13 1999-02-17 Smithkline Beecham Corporation A method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
WO1999011662A1 (en) * 1997-09-05 1999-03-11 Millennium Biotherapeutics, Inc. Novel molecules of the tnfr-ligand-related protein family and uses thereof
WO1999035262A2 (en) * 1998-01-07 1999-07-15 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
WO1999042584A1 (en) * 1998-02-20 1999-08-26 Human Genome Sciences, Inc. Apoptosis inducing molecule ii and methods of use
WO2000010591A1 (en) * 1998-08-18 2000-03-02 The Trustees Of The University Of Pennsylvania Peptides for inhibition of herpes simplex virus entry
WO2000014230A1 (en) * 1998-09-03 2000-03-16 Millennium Pharmaceuticals, Inc. Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof
WO2000021558A1 (en) * 1998-10-09 2000-04-20 Biogen, Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
WO2000053223A1 (en) * 1999-03-11 2000-09-14 Human Genome Sciences, Inc. Apoptosis inducing molecule ii and methods of use

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
HARROP J A ET AL: "Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for (HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 42, 16 October 1998 (1998-10-16), pages 27548 - 27556, XP002109996, ISSN: 0021-9258 *
HARROP J ET AL: "Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 161, no. 4, 15 August 1998 (1998-08-15), pages 1786 - 1794, XP002143292, ISSN: 0022-1767 *
HARROP J ET AL: "HVEM-L, A NOVEL LIGAND FOR HVEM/TR2, STIMULATES NF-KB DEPENDENT TRANSCRIPTION AND T CELL PROLIFERATION", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 18, no. 5, 1998, pages A - 39, XP000914784, ISSN: 1079-9907 *
HUANG T ET AL: "ANTI-IDIOTYPIC ANTIBODIES MIMICKING GLYCOPROTEIN D HOF HERPES SIMPLEX VIRUS IDENTIFY A CELLULAR PROTEIN REQUIRED FOR VIRUS SPREAD FROM CELL TO CELL AND VIRUS-INDUCED POLYKARYOCYTOSIS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, 1 March 1996 (1996-03-01), pages 1836 - 1840, XP002911959, ISSN: 0027-8424 *
KWON B S ET AL: "A NEWLY IDENTIFIED MEMBER OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY WITH A WIDE TISSUE DISTRIBUTION AND INVOLVEMENT IN LYMPHOCYTE ACTIVATION", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 22, 30 May 1997 (1997-05-30), pages 14272 - 14276, XP002062425, ISSN: 0021-9258 *
MAURI D N ET AL: "LIGHT, A NEW MEMBER OF THE TNF SUPERFAMILY, AND LYMPHOTOXIN ALPHA ARE LIGANDS FOR HERPESVIRUS ENTRY MEDIATOR", IMMUNITY, CELL PRESS, US, vol. 8, January 1998 (1998-01-01), pages 21 - 30, XP002915183, ISSN: 1074-7613 *
MONTGOMERY R I ET AL: "HERPES SIMPLEX VIRUS-1 ENTRY INTO CELLS MEDIATED BY A NOVEL MEMBER OF THE TNF/NGF RECEPTOR FAMILY", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 87, 1 November 1996 (1996-11-01), pages 427 - 436, XP002911958, ISSN: 0092-8674 *
PUGLIELLI M T ET AL: "Reversal of virus -induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 5, no. 12, December 1999 (1999-12-01), pages 1370 - 1374, XP002132900, ISSN: 1078-8956 *
ZHAI Y ET AL: "LIGHT, A NOVEL LIGAND FOR LYMPHOTOXIN BETA RECEPTOR AND TR2/HVEM INDUCES APOPTOSIS AND SUPPRESSES IN VIVO TUMOR FORMATION VIA GENE TRANSFER", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 102, no. 6, September 1998 (1998-09-01), pages 1142 - 1151, XP002947576, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
WO2001079496A2 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
DE69842096D1 (en) LIGAND OF THE CELL INTRUSION-PROCESSING PROTEIN OF HERPES SIMPLEX VIRUS AND METHODS FOR ITS USE
CY1111293T1 (en) CONNECTOR FOR MEDIUM ENTRY INTRODUCTION
WO2001079496A3 (en) Ligand for herpes simplex virus entry mediator and methods of use
AU676349B2 (en) Nucleic acid-binding oligomers possessing N-branching for therapy and diagnostics
WO2000066067A3 (en) Ibd-associated microbial antigens and methods of using same
WO2001082786A3 (en) Optical imaging of subsurface anatomical structures and biomolecules
CZ63995A3 (en) Virus vectors and their use in gene therapy
EP0369566A3 (en) Bifunctional chimeric antibodies
WO1999010375A3 (en) Vaccine against hpv
IL189629A0 (en) Compositions containing human ctla-4 antibodies
CA2232242A1 (en) Long wavelength engineered fluorescent proteins
AU1331100A (en) Cancer immunotheraphy and diagnosis using universal tumor associated antigens, including htert
WO1998058965A3 (en) B7-binding molecules for treating immune diseases
WO1996003997A3 (en) Treatment of cancer using hsv mutant
EP0884283A4 (en) FLAT GLASS FORMATION PROCESS
WO2000050588A3 (en) Genes associated with diseases of the colon
AU7161994A (en) nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics
AU5372796A (en) Novel human cytomegalovirus dna sequences
FR2806739B1 (en) GENES INVOLVED IN INFLAMMATORY BOWEL DISEASES AND THEIR USE
EP1452540A3 (en) Molecular sequence of swine retrovirus and methods of use
AU1971295A (en) Humanized monoclonal antibodies against human interleukin-4
WO2003016501A3 (en) Recombinant antibodies, and compositions and methods for making and using the same
WO1998049333A3 (en) Eukaryotic gene expression cassette and uses thereof
AU3505397A (en) Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
DE69130845D1 (en) HLA-DR antigen gene, its nucleotide sequence and use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001253387

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 577479

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2406132

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001926879

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001926879

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001926879

Country of ref document: EP